- Home
- SYBT vs IBRX Comparison
SYBT vs IBRX Comparison
Compare SYBT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- IBRX
- Stock Information
- Founded
- SYBT 1904
- IBRX 2014
- Country
- SYBT United States
- IBRX United States
- Employees
- SYBT N/A
- IBRX N/A
- Industry
- SYBT Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYBT Finance
- IBRX Health Care
- Exchange
- SYBT Nasdaq
- IBRX Nasdaq
- Market Cap
- SYBT 2.1B
- IBRX 2.3B
- IPO Year
- SYBT N/A
- IBRX N/A
- Fundamental
- Price
- SYBT $66.45
- IBRX $2.38
- Analyst Decision
- SYBT Hold
- IBRX Strong Buy
- Analyst Count
- SYBT 3
- IBRX 6
- Target Price
- SYBT $83.67
- IBRX $9.83
- AVG Volume (30 Days)
- SYBT 111.2K
- IBRX 9.8M
- Earning Date
- SYBT 10-29-2025
- IBRX 11-10-2025
- Dividend Yield
- SYBT 1.93%
- IBRX N/A
- EPS Growth
- SYBT 26.14
- IBRX N/A
- EPS
- SYBT 4.58
- IBRX N/A
- Revenue
- SYBT $378,633,000.00
- IBRX $56,600,000.00
- Revenue This Year
- SYBT $16.82
- IBRX $629.94
- Revenue Next Year
- SYBT $5.11
- IBRX $109.91
- P/E Ratio
- SYBT $14.50
- IBRX N/A
- Revenue Growth
- SYBT 14.11
- IBRX 4227.22
- 52 Week Low
- SYBT $60.75
- IBRX $1.83
- 52 Week High
- SYBT $83.83
- IBRX $6.33
- Technical
- Relative Strength Index (RSI)
- SYBT 40.65
- IBRX 43.73
- Support Level
- SYBT $65.69
- IBRX $2.30
- Resistance Level
- SYBT $68.84
- IBRX $2.67
- Average True Range (ATR)
- SYBT 2.04
- IBRX 0.12
- MACD
- SYBT 0.16
- IBRX -0.00
- Stochastic Oscillator
- SYBT 28.64
- IBRX 20.27
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.